The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer–Alliance for Clinical Trials in Oncology–International Society of Geriatric Oncology Position Article
Open accessAbstract
Selecting the most appropriate end points for clinical trials is important to assess the value of new treatment strategies. Well-established end points for clinical research exist in oncology but may not be as relevant to the older cancer population because of competing risks of death and potentially increased impact of therapy on global functioning and quality of life. This article discusses specific clinical end points and their advantages and disadvantages for older individuals. Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations but ideally need to be confirmed in phase III trials, which are unfortunately often hindered by the severe heterogeneity of the older cancer population, difficulties with selection bias depending on inclusion criteria, physician perception, and barriers in willingness to participate. All clinical trials in oncology should be without an upper age limit to allow entry of eligible older adults. In settings where so-called standard therapy is not feasible, specific trials for older patients with cancer might be required, integrating meaningful measures of outcome. Not all questions can be answered in randomized clinical trials, and large observational cohort studies or registries within the community setting should be established (preferably in parallel to randomized trials) so that treatment patterns across different settings can be compared with impact on outcome. Obligatory integration of a comparable form of geriatric assessment is recommended in future studies, and regulatory organizations such as the European Medicines Agency and US Food and Drug Administration should require adequate collection of data on efficacy and toxicity of new drugs in fit and frail elderly subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7625 · Cited by 1,841
Self-citationUnderstanding the Treatment Preferences of Seriously Ill Patients
Fried, T. R., Bradley, E. H., Towle, V. R., & Allore, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012528 · Cited by 1,522
Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J., Levine, R. M., Lubiner, E. T., Reyes, P., Schreiber, F. J., et al. (2012) · Cancer · doi:10.1002/cncr.26646 · Cited by 1,143
Self-citationParticipation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,031
Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Freemantle, N., Calvert, M., Wood, J., Eastaugh, J., & Griffin, C. (2003) · JAMA · doi:10.1001/jama.289.19.2554 · Cited by 783
Section XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Statistical Principles for Clinical Trials
Kay, R. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600201 · Cited by 573
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., Dressler, L. G., Cohen, H. J., Becker, H. P., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810266 · Cited by 554
Self-citationPeyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.-F., Castaigne, S., Coiffier, B., Haioun, C., Bologna, S., Fitoussi, O., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70069-9 · Cited by 553
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help
(2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.11.001 · Cited by 463
Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
Scher, K. S., & Hurria, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6727 · Cited by 432
Self-citationSeymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., O'Mahony, M. S., Maughan, T. S., Parmar, M., & Langley, R. E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60399-1 · Cited by 419
Cordoba, G., Schwartz, L., Woloshin, S., Bae, H., & Gotzsche, P. C. (2010) · BMJ · doi:10.1136/bmj.c3920 · Cited by 400
Value of functional status as a predictor of mortality: Results of a prospective study
Reuben, D. B., Rubenstein, L. V., Hirsch, S. H., & Hays, R. D. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90200-u · Cited by 387
Age and Clinical Decision Making in Oncology Patients
Yellen, S. B., Cella, D. F., & Leslie, W. T. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.23.1766 · Cited by 354
Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401
Hurria, A., Cirrincione, C. T., Muss, H. B., Kornblith, A. B., Barry, W., Artz, A. S., Schmieder, L., Ansari, R., Tew, W. P., Weckstein, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.6985 · Cited by 350
Self-citationEORTC elderly task force position paper: Approach to the older cancer patient
Pallis, A. G., Fortpied, C., Wedding, U., Van Nes, M. C., Penninckx, B., Ring, A., Lacombe, D., Monfardini, S., Scalliet, P., & Wildiers, H. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.022 · Cited by 340
Self-citationUse of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review
Puts, M. T. E., Hardt, J., Monette, J., Girre, V., Springall, E., & Alibhai, S. M. H. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs285 · Cited by 335
Progression-Free Survival: Meaningful or Simply Measurable?
Booth, C. M., & Eisenhauer, E. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7571 · Cited by 324
Tucci, A., Ferrari, S., Bottelli, C., Borlenghi, E., Drera, M., & Rossi, G. (2009) · Cancer · doi:10.1002/cncr.24490 · Cited by 282
Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients
Schairer, C., Mink, P. J., Carroll, L., & Devesa, S. S. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh253 · Cited by 275
Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical Trials
Aapro, M. S., Köhne, C.-H., Cohen, H. J., & Extermann, M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-198 · Cited by 244
Self-citationClinical symptoms and comorbidity: significance for the prognostic classification of cancer
Piccirillo, J. F., & Feinstein, A. R. (1996) · Cancer · Cited by 240
EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors
Pallis, A. G., Ring, A., Fortpied, C., Penninckx, B., Van Nes, M. C., Wedding, U., vonMinckwitz, G., Johnson, C. D., Wyld, L., Timmer-Bonte, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq687 · Cited by 158
Self-citationDrug Policy for an Aging Population — The European Medicines Agency's Geriatric Medicines Strategy
Cerreta, F., Eichler, H., & Rasi, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1209034 · Cited by 138
Pharmacology of Anticancer Drugs in the Elderly Population
Wildiers, H. P. M. W., Highley, M., de Bruijn, E. A., & van Oosterom, A. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342140-00003 · Cited by 135
Self-citationOffen, W., Chuang‐Stein, C., Dmitrienko, A. A., Littman, G. S., Maca, J., Meyerson, L., Muirhead, R. J., Stryszak, P., Baddy, A., Chen, K., et al. (2007) · Drug Information Journal · doi:10.1177/009286150704100105 · Cited by 122
Javid, S. H., Unger, J. M., Gralow, J. R., Moinpour, C. M., Wozniak, A. J., Goodwin, J. W., Lara, P. N., Williams-Piehota, P. A., Hutchins, L. F., Gotay, C. C., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0384 · Cited by 108
Ardizzoni, A., Favaretto, A. G., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., Pari, F., Tibaldi, C., Altieri, A. M., Barbera, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.140 · Cited by 88
Johnson, C., Fitzsimmons, D. F., Gilbert, J., Arrarras, J.-I., Hammerlid, E. B., Brédart, A., Özmen, M. M., Dilektaşlı, E., Coolbrandt, A., Kenis, C., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.014 · Cited by 84
Brain, E. G. C., Mertens, C., Girre, V., Rousseau, F., Blot, E., Abadie, S., Uwer, L., Bourbouloux, E., Praagh-Doreau, I. V., Mourey, L., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.10.003 · Cited by 56
Pallis, A. G., Agelaki, S., Kakolyris, S., Kotsakis, A. P., Kalykaki, A., Vardakis, N., Papakotoulas, P., Agelidou, A., Geroyianni, A., Agelidou, M., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.03.030 · Cited by 48
Self-citationPredictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
Laskey, R. A., Poniewierski, M. S., Lopez, M. A., Hanna, R. K., Secord, A. A., Gehrig, P. A., Lyman, G. H., & Havrilesky, L. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.03.015 · Cited by 42
Clinical trial design in older adults with cancer—The need for new paradigms
Lichtman, S. M. (2012) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2012.03.002 · Cited by 33
Self-citationPallis, A. G., Karampeazis, A., Vamvakas, L., Vardakis, N., Kotsakis, A. P., Bozionelou, V., Kalykaki, A., Hatzidaki, D., Mavroudis, D., & Georgoulias, V. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq772 · Cited by 20
Self-citationA call for observational cohort studies in geriatric oncology
Mohile, S. G., & Wildiers, H. P. M. W. (2012) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2012.04.006 · Cited by 12
Self-citation
Cited by
Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L. G., Extermann, M., Falandry, C., Artz, A., Brain, E., Colloca, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8347 · Cited by 1,831
Self-citationChemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Sedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Self-citationHurria, A., Levit, L. A., Dale, W., Mohile, S. G., Muss, H. B., Fehrenbacher, L., Magnuson, A., Lichtman, S. M., Bruinooge, S. S., Soto-Perez-de-Celis, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0319 · Cited by 419
Self-citation
Metadata
- Authors
- Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S. G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S. M., Ballman, K., Cohen, H. J., Muss, H., & Wedding, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-10
- Volume
- 31
- Issue
- 29
- Pages
- 3711-3718
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156875127
- Cited by
- 322
- References
- 39
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.